Tickers

1. Composite Trajectory Verdict

For a pre-revenue biopharmaceutical company, the cash flow statement and balance sheet (liquidity/runway) matter most because they determine the ability to fund operations until potential product approval; the income statement primarily reflects the timing of R&D spend and one-time charges.

Composite Trajectory: Mixed

The annual income statement shows a narrowing net loss (FY 2025 $(154.7M) vs FY 2024 $(177.8M)) (10-K 2025-12-31, Consolidated Statements of Operations), but the quarterly trajectory deteriorated sharply in Q2 2026 due to a $200M Tanabe license payment expensed as R&D (10-Q 2026-06-30, Condensed Statements of Operations). Cash flow from operations improved modestly on both an annual (FY 2025 $(142.4M) vs FY 2024 $(166.3M)) and six-month basis (H1 2026 $(72.0M) vs H1 2025 $(75.7M)) (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Condensed Statements of Cash Flows). Total liquid resources (cash + investments) remained stable near $650-660M across periods (10-K 2025-12-31, Balance Sheets; 10-Q 2026-03-31, Condensed Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets). The balance sheet shows equity declining in H1 2026 (from $646.7M to $550.9M) as losses outpaced equity raises, while a $100M term loan was added (10-Q 2026-06-30, Condensed Balance Sheets; Note 6).

2. Red Flags

• Large one-time R&D charge distorting quarterly loss trend: Q2 2026 R&D expense of $221.4M includes a $200M upfront payment to Tanabe under the Fourth Amendment, causing net loss to jump to $(241.1M) vs $(43.3M) in Q2 2025 (10-Q 2026-06-30, Condensed Statements of Operations; MD&A).
• Accelerating G&A spend: G&A rose from $23.8M (FY 2024) to $38.6M (FY 2025) to $45.6M (H1 2026 annualized ~$91M), driven by headcount, professional fees, and pre-commercial build-out (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Condensed Statements of Operations).
• Equity erosion despite large raises: Stockholders' equity fell from $646.7M (Dec 2025) to $550.9M (June 2026) even after $143.9M public offering, $20.2M ATM sales, and $96.5M loan proceeds, because H1 2026 net loss of $280.4M exceeded financing inflows (10-Q 2026-06-30, Condensed Statements of Stockholders' Equity; Condensed Statements of Cash Flows).
• New debt with revenue covenant: The $500M term loan facility includes a minimum trailing twelve-month consolidated net product revenue covenant tested quarterly starting March 31, 2029, and maturity accelerates to June 30, 2028 if FDA approval is not obtained by Sept 30, 2027 (10-Q 2026-06-30, Note 6).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: The full-year net loss narrowed from $(177.8M) in FY 2024 to $(154.7M) in FY 2025 as R&D fell $36.6M (pivotal trials concluded) while G&A rose $14.8M (10-K 2025-12-31, Consolidated Statements of Operations; MD&A). In Q1 2026, net loss improved to $(39.3M) from $(42.2M) in Q1 2025, with R&D down $13.5M and G&A up $14.4M (10-Q 2026-03-31, Condensed Statements of Operations). In Q2 2026, net loss surged to $(241.1M) from $(43.3M) in Q2 2025, driven by the $200M Tanabe upfront payment recorded as R&D expense (10-Q 2026-06-30, Condensed Statements of Operations; MD&A). Excluding that item, underlying R&D spend continued to decline as clinical trials wind down, but G&A continues to rise steadily with pre-commercial hiring and professional fees.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Stable

Overall Assessment: Net cash used in operating activities improved modestly year-over-year: FY 2025 $(142.4M) vs FY 2024 $(166.3M) (10-K 2025-12-31, Consolidated Statements of Cash Flows); H1 2026 $(72.0M) vs H1 2025 $(75.7M) (10-Q 2026-06-30, Condensed Statements of Cash Flows). Investing cash flows reflect portfolio management of marketable securities: FY 2025 saw net outflows of $(389.8M) vs inflows of $115.0M in FY 2024; H1 2026 net outflows of $(230.2M) included the $200M Tanabe payment (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Condensed Statements of Cash Flows). Financing inflows remained robust: FY 2025 $591.0M (public offerings + ATM); H1 2026 $267.5M (public offering $143.9M, term loan $96.5M, ATM $20.2M) (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Condensed Statements of Cash Flows). Total cash, cash equivalents, and investments held near $650-660M across Dec 2025 ($656.6M), Mar 2026 ($646.1M), and Jun 2026 ($661.4M) (10-K 2025-12-31, Balance Sheets; 10-Q 2026-03-31, Condensed Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets grew from $205.9M (Dec 2024) to $661.8M (Dec 2025) following large equity raises, then held roughly flat at $652.9M (Mar 2026) and $667.9M (Jun 2026) (10-K 2025-12-31, Balance Sheets; 10-Q 2026-03-31, Condensed Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets). Stockholders' equity peaked at $646.7M (Dec 2025) but declined to $638.1M (Mar 2026) and $550.9M (Jun 2026) as accumulated deficit grew from $(457.2M) to $(496.5M) to $(737.6M) (10-K 2025-12-31, Balance Sheets; 10-Q 2026-03-31, Condensed Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets). A senior secured term loan of $97.6M (net) appeared on the balance sheet at Jun 2026 (Tranche A drawn) (10-Q 2026-06-30, Condensed Balance Sheets; Note 6). Current liabilities rose modestly from $15.1M (Dec 2025) to $19.3M (Jun 2026), driven by higher accrued R&D ($6.8M vs $3.5M) and professional fees ($7.3M vs $4.1M) (10-K 2025-12-31, Balance Sheets; 10-Q 2026-06-30, Note 4).

6. Data Gaps

• Standalone Q3 2025 and Q4 2025 quarterly income statements and cash flows (only annual FY 2025 and Q1/Q2 2026 quarters are available).
• Quarterly breakdown of FY 2024 (only annual figures in 10-K; Q1-Q3 2024 10-Qs not provided).
• Detailed maturity profile of marketable securities beyond the held-to-maturity Treasury bill schedule in Note 3.
• Interest expense detail for the term loan beyond the $0.8M recognized in Q2 2026 (10-Q 2026-06-30, Note 6).
• Post-Jun 2026 ATM activity (filing notes $20.2M sold through Mar 12, 2026, but no update for Apr-Jun 2026 beyond "no shares sold in Q2 2026").